Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

PHASE2CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

July 31, 2010

Study Completion Date

December 31, 2010

Conditions
Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2Diabetic Polyneuropathy
Interventions
BIOLOGICAL

SB-509

60 mg dose

OTHER

Placebo

Saline

Trial Locations (20)

10022

Peripheral Neuropathy Center, Weill Medical College of Cornell University, New York

10032

Neurological Institute Columbia University College of Physicians and Surgeons, New York

12205

Upstate Clinical Research, Albany

16635

Altoona Center for Clinical Research, Duncansville

33351

Neurology Clinical Research, Sunrise

33407

Laszlo J. Mate', M.D., West Palm Beach

34205

Bradenton Research Center, Bradenton

66160

University of Kansas Medical Center, Kansas City

68131

Creighton Diabetes Center, Omaha

77030

Nerve and Muscle Center of Texas, Houston

78229

DGD Research, San Antonio

79705

Diabetes Center of the Southwest, Midland

89123

Advanced Biomedical Research of America, Las Vegas

90707

Torrance Clinical Research, Lomita

90712

Advanced Medical Research, LLC, Lakewood

92037

Coordinated Clinical Research, La Jolla

94109

SF Clinical Research Center, San Francisco

94598

Diablo Clinical Research, Walnut Creek

98057

Rainier Clinical Research Center, Renton

06700

Instituto Mexicano de Investigación Clinica, Mexico City

Sponsors
All Listed Sponsors
lead

Sangamo Therapeutics

INDUSTRY